MSV-allo
/ Citospin, Red de Terapia Celular
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
July 25, 2025
MSV_LE: Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
(clinicaltrials.gov)
- P2 | N=20 | Recruiting | Sponsor: Red de Terapia Celular | Trial completion date: Jul 2026 ➔ Dec 2027 | Trial primary completion date: Jul 2025 ➔ Dec 2026
Trial completion date • Trial primary completion date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
April 10, 2024
MSV_LE: Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
(clinicaltrials.gov)
- P2 | N=20 | Recruiting | Sponsor: Red de Terapia Celular | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2024 ➔ Jul 2025
Trial completion date • Trial primary completion date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
April 04, 2023
MSV_LE: Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
(clinicaltrials.gov)
- P2 | N=20 | Recruiting | Sponsor: Red de Terapia Celular | Not yet recruiting ➔ Recruiting
Enrollment open • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
December 21, 2022
MSV_LE: Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
(clinicaltrials.gov)
- P2 | N=20 | Not yet recruiting | Sponsor: Red de Terapia Celular | N=36 ➔ 20 | Trial completion date: Jun 2024 ➔ Jul 2025 | Trial primary completion date: Dec 2023 ➔ Jul 2024
Enrollment change • Trial completion date • Trial primary completion date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
June 07, 2022
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)
(clinicaltrials.gov)
- P2 | N=24 | Completed | Sponsor: Red de Terapia Celular | Recruiting ➔ Completed
Trial completion • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases
May 27, 2022
LUPUS NEPHRITIS TREATMENT WITH MESENCHYMAL CELLS (MSV-allo®). TRATAMIENTO DE LA NEFRITIS LÚPICA con células mesenquimales (MSV-allo®).
(clinicaltrialsregister.eu)
- P2 | N=20 | Ongoing | Sponsor: Hospital Universitario Rio Hortega
New P2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
March 10, 2021
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)
(clinicaltrials.gov)
- P2; N=24; Recruiting; Sponsor: Red de Terapia Celular; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Nov 2020 ➔ Nov 2021
Clinical • Trial completion date • Trial primary completion date • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases
April 29, 2020
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)
(clinicaltrials.gov)
- P2; N=24; Recruiting; Sponsor: Red de Terapia Celular; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
April 24, 2020
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)
(clinicaltrials.gov)
- P2; N=24; Not yet recruiting; Sponsor: Red de Terapia Celular
Clinical • New P2 trial
April 14, 2020
Treatment of COVID-19 with allogeneic mesenchymal cells (MSV®). Tratamiento de COVID-19 con células mesenquimales alogénicas MSV®
(clinicaltrialsregister.eu)
- P2; N=24; Ongoing; Sponsor: CITOSPIN S.L.
Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases
1 to 10
Of
10
Go to page
1